

DAFTAR PUSTAKA

1. Feller-Kopman DJ, Reddy CB, Gould MK, Balekian AA, DeCamp MM, Diekemper RL, et al. Management of malignant pleural effusions: An official ATS/STS/STR clinical practice guideline. *Am J Respir Crit Care Med*. 2018;198(7):839–49.
2. Kulandaisamy PC, Kulandaisamy S, Kramer D, McGrath C. Malignant pleural effusions—a review of current guidelines and practices. *J Clin Med*. 2021;10(23):1–7.
3. Roberts ME, Rahman NM, Maskell NA, Bibby AC, Blyth KG, Corcoran JP, et al. British Thoracic Society Guideline for pleural disease. *Thorax*. 2023 Jul;78(Suppl 3):1–42.
4. Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, et al. Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis. *Lancet Oncol*. 2018 Jul;19(7):930–9.
5. Gayen S. Malignant Pleural Effusion: Presentation, Diagnosis, and Management. *Am J Med*. 2022 Oct;135(10):1188–92.
6. Hofmann H-S, Scheule AM, Markowiak T, Ried M. The Treatment of Malignant Pleural Effusion With Permanent Indwelling Pleural Catheters. *Dtsch Arztebl Int*. 2022 Sep;119(35–36):595–600.
7. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: from bench to bedside. *Eur Respir Rev an Off J Eur Respir Soc*. 2016 Jun;25(140):189–98.
8. Tian P, Qiu R, Wang M, Xu S, Cao L, Yang P, et al. Prevalence, Causes, and Health Care Burden of Pleural Effusions Among Hospitalized Adults in China. *JAMA Netw open*. 2021 Aug;4(8):1–5.
9. Sakti BT, Rosalina R, Pradipta J. Characteristics of Chest X-Ray in Patients with Cancer at the Dharmais Cancer Hospital Emergency Room during the COVID-19 Pandemic. *Indones J Cancer*; 2021;195–1.
10. Thompson JC, Ma KC. Malignant Pleural Effusions. In: Fishman's

Pulmonary Diseases and Disorders. 6th ed. Amerika Serikat: McGraw-Hill Education; 2023. p. 1339–50.

11. Taghizadeh N, Marc F, Tremblay A. US Hospitalizations for Malignant Pleural Effusions: Data From the 2012 National Inpatient Sample. *Chest*. 2017;151:845–54.
12. Koyner FG, Chamay S, Barrera N, Arias-Sanchez P, Chong DH. Analyzing Epidemiological Shifts in Malignant Pleural Effusions: Insights From the National Inpatient Sample, 2016–2021. *Chest*. 2024;166(4):1.
13. Arora RD, Boster J. Malignant Pleural Effusion. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
14. Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, et al. ERS/EACTS statement on the management of malignant pleural effusions. *Eur J Cardio-Thoracic Surg*. 2018;55(1):116–32.
15. Aydin Y, Turkyilmaz A, Intepe YS, Eroglu A. Malignant pleural effusions: appropriate treatment approaches. *Eurasian J Med*. 2009 Dec;41(3):186–93.
16. Feller-Kopman D, Light R. Pleural Disease. *N Engl J Med*. 2018 Feb;378(8):740–51.
17. Novakov I, Sterev F. Survival of patients with malignant pleural effusions: a three-year prospective self-experience study. *Eur Respir Soc*. 2018;52:1.
18. Kouritas VK, Hatzoglou C, Foroulis CN, Hevas A, Gourgoulisanis KI, Molyvdas PA. Low glucose level and low pH alter the electrochemical function of human parietal pleura. *Eur Respir J*. 2007;30(2):354–7.
19. Amin Z, Iskandar SD, Sibli. Prognostic Factors of 30-day Survival of Patients with Malignant Pleural Effusion. *Indian J Palliat Care*. 2017;23(3):321–4.
20. Bielsa S, Salud A, Martínez M, Esquerda A, Martín A, Rodríguez-Panadero F, et al. Prognostic significance of pleural fluid data in patients with malignant effusion. *Eur J Intern Med*. 2008 Jul;19(5):334–9.
21. Jiménez D, Díaz G, Gil D, Cicero A, Pérez-Rodríguez E, Sueiro A, et al. Etiology and prognostic significance of massive pleural effusions. *Respir Med*. 2005;99(9):1183–7.

22. Hughes SM, Carmichael JJ. Malignant Pleural Effusions: Updates in Diagnosis and Management. *Life* (Basel, Switzerland). 2022 Dec;13(1):1–12.
23. Adeoye PO, Johnson WR, Desalu OO, Ofoegbu CP, Fawibe AE, Salami AK, et al. Etiology, clinical characteristics, and management of pleural effusion in Ilorin, Nigeria. *Niger Med J*. 2017;58(2):76–80.
24. Herrera Lara S, Fernández-Fabrellas E, Juan Samper G, Marco Buades J, Andreu Lapiedra R, Pinilla Moreno A, et al. Predicting Malignant and Paramalignant Pleural Effusions by Combining Clinical, Radiological and Pleural Fluid Analytical Parameters. *Lung*. 2017;195(5):653–60.
25. Haberal M, Sengoren Dikis O, Akar E. Evaluation of Pleural Effusions: Malignant and Paramalignant. *Akdeniz Med J*. 2019;203–8.
26. Dermawan JKT, Policarpio-Nicolas ML. Malignancies in Pleural, Peritoneal, and Pericardial Effusions. *Arch Pathol Lab Med*. 2020 Sep;144(9):1086–91.
27. Deniz S, Gulce Z, Emre J, Alizoroglu D, Erbaycu A. May Biochemical Variables and Pleural Fluid Cell Count Be Used in the Benign- Malign Differentiation of Pleural Effusions Associated with Lung Cancer? *Bezmialem Sci*. 2019;7:18–22.
28. Quek JC, Tan QL, Allen JC, Anantham D. Malignant pleural effusion survival prognostication in an Asian population. *Respirology*. 2020 Dec;25(12):1283–91.
29. Sidiq MF, Agustina H, Kulsum ID. Profil klinis, gambaran makroskopis dan mikroskopis cairan efusi pleura pada pasien rawat inap di departemen ilmu penyakit dalam RSUP dr. Hasan Sadikin Bandung periode Januari 2016-Desember 2018. *Indones J Chest*. 2020;7(1):h. 1-10.
30. Zamboni MM, da Silva CTJ, Baretta R, Cunha ET, Cardoso GP. Important prognostic factors for survival in patients with malignant pleural effusion. *BMC Pulm Med*. 2015 Mar;15:29.
31. Psallidas I, Kalomenidis I, Porcel JM, Robinson BW, Stathopoulos GT. Malignant pleural effusion: From bench to bedside. *Eur Respir Rev*.

- 2016;25(140):189–98.
32. Uzbek MH, Almeida FA, Sarkiss M, Morice RC, Jimenez CA, Eapen GA, et al. Management of malignant pleural effusions. *Adv Ther.* 2010;27:334–47.
 33. Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. *Respirology.* 2015;20(4):654–9.
 34. Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive effusions. *Chest.* 2003;124(3):978–83.
 35. DeBiasi EM, Pisani MA, Murphy TE, Araujo K, Kookoolis A, Argento AC, et al. Mortality among patients with pleural effusion undergoing thoracentesis. *Eur Respir J.* 2015 Aug;46(2):495–502.
 36. Burks AC, Rivera MP. Clinical Evaluation, Diagnosis, and Staging of Lung Cancer. In: Grippi MA, Antin-Ozerkis DE, Della Cruz CS, Kotloff RM, Kotton CN, Pack AI, editors. *Fishman's Pulmonary Diseases and Disorders.* 6th ed. New York, USA: McGraw-Hill Education; 2023. p. 1950–63.
 37. Porcel JM, Vives M. Etiology and pleural fluid characteristics of large and massive effusions. *Chest.* 2003 Sep;124(3):978–83.
 38. Montero-Arias F, Cartin-Ceba R, Rojas-Solano JR, Ugalde-Gamboa L, Ramos-Esquivel A. Pleural Effusion Size as Prognostic Marker in Patients With Malignant Pleural Effusion: A Retrospective Cohort Study. *PLEURA.* 2015;1–5.
 39. Kasapoglu US, Arınç S, Gungör S, Irmak I, Guney P, Aksoy F, et al. Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions. *Clin Respir J.* 2016 Nov;10(6):791–9.
 40. Skok K, Hladnik G, Grm A, Crnjac A. Malignant pleural effusion and its current management: A review. *Med.* 2019;55(8):1–21.
 41. Davies HE, Stermann D, Lee YCG. Pleural Malignancy. In: Murray & Nadel's Textbook of Respiratory Medicine. 7th ed. Philadelphia: Elsevier Inc; 2022. p. 1575–89.

42. Abrao FC, Peixoto RD, de Abreu IRLB, Janini MC, Viana GG, de Oliveira MC, et al. Prognostic factors in patients with malignant pleural effusion: Is it possible to predict mortality in patients with good performance status? *J Surg Oncol.* 2016 Apr;113(5):570–4.
43. Ozyurtkan MO, Balci AE, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion. *Eur J Intern Med.* 2010 Feb;21(1):30–4.
44. Qiao X, Zhang Z-R, Shi X-Y, Yi F-S. Total Protein-Chloride Ratio in Pleural Fluid Independently Predicts Overall Survival in Malignant Pleural Effusion at the First Diagnosis. *Front Oncol.* 2021;11:1–8.
45. Martínez-Moragón E, Aparicio J, Sanchis J, Menéndez R, Cruz Rogado M, Sanchis F. Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. *Respiration.* 1998;65(2):108–13.
46. Clive AO, Kahan BC, Hooper CE, Bhatnagar R, Morley AJ, Zahan-Evans N, et al. Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. *Thorax.* 2014 Dec;69(12):1098–104.
47. Valvona CJ, Fillmore HL, Nunn PB, Pilkington GJ. The Regulation and Function of Lactate Dehydrogenase A: Therapeutic Potential in Brain Tumor. *Brain Pathol.* 2016 Jan;26(1):3–17.
48. Verma A, Abisheganaden J, Light RW. Identifying Malignant Pleural Effusion by A Cancer Ratio (Serum LDH: Pleural Fluid ADA Ratio). *Lung.* 2016 Feb;194(1):147–53.
49. Mishra D, Banerjee D. Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment. *Cancers (Basel).* 2019;11(6):1–21.
50. Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K. The usefulness of lactate dehydrogenase measurements in current oncological practice. *Cell Mol Biol Lett.* 2020;25(1):1–15.
51. Fitzgerald DB, Leong SL, Budgeon CA, Murray K, Rosenstengal A, Smith

- NA, et al. Relationship of pleural fluid pH and glucose: a multi-centre study of 2,971 cases. *J Thorac Dis.* 2019 Jan;11(1):123–30.
52. Management of malignant pleural effusions. *Am J Respir Crit Care Med.* 2000 Nov;162(5):1987–2001.
53. Rodriguez-Panadero F, Lopez-Mejias J. Low glucose and pH levels in malignant effusions. *Am Rev Respir Dis.* 1989;139–663.
54. Kapp CM, Lee HJ. Malignant Pleural Effusions. *Clin Chest Med.* 2021;42(4):687–96.
55. Saha K, Maikap MK, Maji A, Moitra M, Jash D. Demographic, clinical, biochemical, radiological and etiological characteristics of malignant pleural effusions from Eastern India. *Indian J Cancer.* 2017;54(1):257–61.
56. Rodriguez EF, Chowsilpa S, Maleki Z. The Differential Diagnosis in Nonlymphoproliferative Malignant Pleural Effusion Cytopathology and Its Correlation with Patients' Demographics. *Acta Cytol.* 2018;62(5–6):436–42.
57. George LJ, Turk E, Oh Y, Vallejo A, Caputi A, Gupta S. A nationwide analysis of demographic and treatment patterns in admissions for malignant pleural effusions from 2016-2020. *J Clin Oncol.* 2024;42(16 supplement):1618.
58. Foote DC, Burke CR, Pandian B, Banks S, Haug KL, Hipp M, et al. Gender Disparity in Referral for Definitive Care of Malignant Pleural Effusions. *J Surg Res.* 2019 Dec;244:409–16.
59. Eisenhauer EL, D'Angelica MI, Abu-Rustum NR, Sonoda Y, Jarnagin WR, Barakat RR, et al. Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer. *Gynecol Oncol.* 2006 Dec;103(3):871–7.
60. Light RW. Pleural diseases: Sixth edition. *Pleural Diseases: Sixth Edition.* 2013. 1–504 p.
61. Sabri YY, Mahmoud IH, El-Gendy LT, Abd El-Mageed MR, Tadros SF. Added value of diffusion-weighted MRI in assessment of pleural lesions. *Egypt J Radiol Nucl Med.* 2021;52(1):184.
62. Wu S-G, Yu C-J, Tsai M-F, Liao W-Y, Yang C-H, Jan I-S, et al. Survival of

- lung adenocarcinoma patients with malignant pleural effusion. *Eur Respir J*. 2013 Jun;41(6):1409–18.
63. Putri KSA, Rai IBN, Kusumawardani IAJD, Candrawati NW, Sajinadiyasa IGK, Arisanti NLPE. The Relationship of Lactate Dehydrogenase, PH, Glucose and Protein Pleural Fluids with One Year Life of Patients with Non-small Cell Lung Carcinoma with Malignant Pleural Effusion in Prof. Dr IGNG Ngoerah Denpasar. *Int J Health Sci (Qassim)*. 2022;6:4397–416.
64. Peng P, Yang Y, Du J, Zhai K, Shi H-Z. Prognostic biomarkers of malignant patients with pleural effusion: a systematic review and meta-analysis. *Cancer Cell Int*. 2022 Feb;22(1):99.
65. Aleksiev V, Markov D, Yavorov B, Bechev K, Markov G, Shterev F, et al. Enhanced diagnostic approaches for malignant pleural effusions: an extensive biochemical and statistical analysis. *Folia Med (Plovdiv)*. 2025;67:1–11.
66. Bonta I, Thompson P, Parks C, Bonta D, Bechara R. P2.04-040 Pleural Effusion Characteristics and Relationship with Outcomes in Cancer Patients: Topic: Esophageal Cancer and Other Malignancies. *J Thorac Oncol* [Internet]. 2017 Jan 1;12(1):S1021. Available from: <https://doi.org/10.1016/j.jtho.2016.11.1420>
67. Hooper C, Lee YCG, Maskell N. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. *Thorax*. 2010 Aug;65 Suppl 2:4–17.